Literature DB >> 22723360

Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Daniela Tudor1, Huifeng Yu, Julien Maupetit, Anne-Sophie Drillet, Tahar Bouceba, Isabelle Schwartz-Cornil, Lucia Lopalco, Pierre Tuffery, Morgane Bomsel.   

Abstract

The constant heavy chain (CH1) domain affects antibody affinity and fine specificity, challenging the paradigm that only variable regions contribute to antigen binding. To investigate the role of the CH1 domain, we constructed IgA2 from the broadly neutralizing anti-HIV-1 2F5 IgG1, and compared 2F5 IgA2 and IgG binding affinity and functional activities. We found that 2F5 IgA2 bound to the gp41 membrane proximal external region with higher affinity than IgG1. Functionally, compared with IgG1, 2F5 IgA2 more efficiently blocked HIV-1 transcytosis across epithelial cells and CD4(+) cell infection by R5 HIV-1. The 2F5 IgG1 and IgA2 acted synergistically to fully block HIV-1 transfer from Langerhans to autologous CD4(+) T cells and to inhibit CD4(+) T-cell infection. Epitope mapping performed by screening a random peptide library and in silico docking modeling suggested that along with the 2F5 IgG canonical ELDKWA epitope on gp41, the IgG1 recognized an additional 3D-conformational epitope on the gp41 C-helix. In contrast, the IgA2 epitope included a unique conformational motif on the gp41 N-helix. Overall, the CH1 region of 2F5 contributes to shape its epitope specificity, antibody affinity, and functional activities. In the context of sexually transmitted infections such as HIV-1/AIDS, raising a mucosal IgA-based vaccine response should complement an IgG-based vaccine response in blocking HIV-1 transmission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723360      PMCID: PMC3412007          DOI: 10.1073/pnas.1200024109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Can isotype switch modulate antigen-binding affinity and influence clonal selection?

Authors:  O Pritsch; C Magnac; G Dumas; J P Bouvet; P Alzari; G Dighiero
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Immunology of the human genital tract.

Authors:  Martina Johansson; Nils Y Lycke
Journal:  Curr Opin Infect Dis       Date:  2003-02       Impact factor: 4.915

4.  Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.

Authors:  Fangbing Liu; Pablo Lopez Bergami; Mark Duval; David Kuhrt; Marshall Posner; Lisa Cavacini
Journal:  AIDS Res Hum Retroviruses       Date:  2003-07       Impact factor: 2.205

5.  Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1.

Authors:  Patricia B Furtado; Patrick W Whitty; Alexis Robertson; Julian T Eaton; Adel Almogren; Michael A Kerr; Jenny M Woof; Stephen J Perkins
Journal:  J Mol Biol       Date:  2004-05-14       Impact factor: 5.469

6.  Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.

Authors:  Lakshmanan Ganesh; Kwanyee Leung; Karin Loré; Reuven Levin; Amos Panet; Owen Schwartz; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

Authors:  A Alfsen; P Iniguez; E Bouguyon; M Bomsel
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

8.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.

Authors:  Claudia Devito; Jorma Hinkula; Rupert Kaul; Joshua Kimani; Peter Kiama; Lucia Lopalco; Claudia Barass; Stefania Piconi; Daria Trabattoni; Job J Bwayo; Francis Plummer; Mario Clerici; Kristina Broliden
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-01       Impact factor: 3.731

10.  Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

Authors:  Susanne Wolbank; Renate Kunert; Gabriela Stiegler; Hermann Katinger
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  68 in total

1.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

2.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

4.  Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains.

Authors:  Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  Protein Eng Des Sel       Date:  2016-11-29       Impact factor: 1.650

5.  Variable region identical immunoglobulins differing in isotype express different paratopes.

Authors:  Alena Janda; Ertan Eryilmaz; Antonio Nakouzi; David Cowburn; Arturo Casadevall
Journal:  J Biol Chem       Date:  2012-08-28       Impact factor: 5.157

6.  Immunoglobulin isotype influences affinity and specificity.

Authors:  Arturo Casadevall; Alena Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

8.  Local and global anatomy of antibody-protein antigen recognition.

Authors:  Meryl Wang; David Zhu; Jianwei Zhu; Ruth Nussinov; Buyong Ma
Journal:  J Mol Recognit       Date:  2017-12-08       Impact factor: 2.137

9.  Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.

Authors:  Ali Danesh; Yanqin Ren; R Brad Jones
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

10.  Anti-DNA antibody mediated catalysis is isotype dependent.

Authors:  Yumin Xia; Ertan Eryilmaz; Qiuting Zhang; David Cowburn; Chaim Putterman
Journal:  Mol Immunol       Date:  2015-12-01       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.